- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
Patent holdings for IPC class C07D 417/04
Total number of patents in this class: 4000
10-year publication summary
|
294
|
321
|
266
|
314
|
345
|
295
|
281
|
231
|
243
|
59
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 5080 |
97 |
| Novartis AG | 11238 |
60 |
| F. Hoffmann-La Roche AG | 7958 |
54 |
| Janssen Pharmaceutica N.V. | 3839 |
54 |
| Merck Sharp & Dohme LLC | 3689 |
50 |
| Merck Patent GmbH | 5909 |
49 |
| Boehringer Ingelheim International GmbH | 4629 |
47 |
| Bayer AG | 3045 |
46 |
| Vertex Pharmaceuticals Incorporated | 1581 |
44 |
| VALO Health, Inc. | 147 |
42 |
| Syngenta Participations AG | 4970 |
39 |
| Hoffmann-La Roche Inc. | 3060 |
37 |
| Amgen Inc. | 3779 |
36 |
| Rigel Pharmaceuticals, Inc. | 613 |
36 |
| Abbvie Inc. | 1808 |
33 |
| Takeda Pharmaceutical Company Limited | 2961 |
31 |
| Bayer Cropscience AG | 2241 |
30 |
| Dana-Farber Cancer Institute, Inc. | 2455 |
30 |
| Genentech, Inc. | 3742 |
27 |
| Gilead Sciences, Inc. | 1879 |
27 |
| Other owners | 3131 |